Literature DB >> 22186166

Arrhythmias in cardiac sarcoidosis: diagnosis and treatment.

Pablo B Nery1, Eugene Leung, David H Birnie.   

Abstract

PURPOSE OF REVIEW: Sarcoidosis is a granulomatous disease of unclear cause and variable presentation. Cardiac involvement can result in life-threatening conditions including heart block, ventricular tachycardia, sudden cardiac death, and heart failure. There is no consensus on the diagnosis and management of cardiac sarcoidosis and a practical update is needed to provide clinicians with guidance. RECENT
FINDINGS: Three recent studies have described cardiac manifestations as the first presentation of sarcoidosis. In one study, cardiac sarcoidosis was found to be the underlying cause in 19% of adults aged less than 55 years presenting with new onset unexplained atrioventricular block. Also, there are increasing reports of patients with isolated cardiac sarcoidosis (i.e., without sarcoid in other organs). Finally, advances in imaging have enhanced our ability to detect myocardial involvement and perhaps follow response to treatment.
SUMMARY: Cardiac sarcoidosis should be considered in patients aged less than 55 years presenting with unexplained atrioventricular block and in patients with idiopathic cardiomyopathy and sustained ventricular tachycardia. Much remains to be learned about the condition, including the role of steroids and devices in treatment, and the place of advanced imaging in following the response to treatment. Collaborative multicenter studies are required to answer these important clinical questions.

Entities:  

Mesh:

Year:  2012        PMID: 22186166     DOI: 10.1097/HCO.0b013e32834e4c7c

Source DB:  PubMed          Journal:  Curr Opin Cardiol        ISSN: 0268-4705            Impact factor:   2.161


  18 in total

1.  Phase-4 paroxysmal atrioventricular block in sarcoidosis.

Authors:  B Sensoy; O Ozeke; U Canpolat; A Colak; E Grbovic; S Cay; S Topaloglu; D Aras; S Aydogdu
Journal:  Herz       Date:  2013-12-04       Impact factor: 1.443

2.  Cardiac sarcoidosis and ventricular arrhythmias. A rare association of a rare disease. A retrospective cohort study from the National Inpatient Sample and current evidence for management.

Authors:  Amr Salama; Abdullah Abdullah; Abdul Wahab; George Eigbire; Ryan Hoefen; Richard Alweis
Journal:  Cardiol J       Date:  2018-09-20       Impact factor: 2.737

Review 3.  Cardiac sarcoidosis.

Authors:  Matthew M Zipse; William H Sauer
Journal:  Curr Cardiol Rep       Date:  2014-08       Impact factor: 2.931

Review 4.  A complete heart block in a young male: a case report and review of literature of cardiac sarcoidosis.

Authors:  Brijesh Patel; Mahek Shah; Alehegn Gelaye; Raman Dusaj
Journal:  Heart Fail Rev       Date:  2017-01       Impact factor: 4.214

5.  What type of different clinical manifestations can cardiac sarcoidosis present?

Authors:  Ayşegül Şentürk; Yüksel Maraş; Emine Argüder; Ayşegül Karalezli; H Canan Hasanoğlu; Tuba Öğüt; Serdal Baştuğ; Ercan Karabekir
Journal:  Rheumatol Int       Date:  2014-11-28       Impact factor: 2.631

6.  Outcomes of patients with definite and suspected isolated cardiac sarcoidosis treated with an implantable cardiac defibrillator.

Authors:  Jordana Kron; William Sauer; Gisela Mueller; Joseph Schuller; Frank Bogun; Sinan Sarsam; Lynda Rosenfeld; Teferi Y Mitiku; Joshua M Cooper; Davendra Mehta; Arnold J Greenspon; Matthew Ortman; David B Delurgio; Ravinder Valadri; Calambur Narasimhan; Nalla Swapna; Jagmeet P Singh; Stephan Danik; Steven M Markowitz; Adrian K Almquist; Andrew D Krahn; Luke G Wolfe; Shawn Feinstein; Kenneth A Ellenbogen; Thomas Crawford
Journal:  J Interv Card Electrophysiol       Date:  2015-02-13       Impact factor: 1.900

7.  Prediction of severe cardiac involvement by fundus lesion in sarcoidosis.

Authors:  Akihiko Umazume; Takeshi Kezuka; Yoko Okunuki; Masayo Ooshita; Yoshihiko Usui; Masaharu Hirano; Akira Yamashina; Hiroshi Goto
Journal:  Jpn J Ophthalmol       Date:  2013-11-12       Impact factor: 2.447

Review 8.  The role of F(18)-fluorodeoxyglucose positron emission tomography in guiding diagnosis and management in patients with known or suspected cardiac sarcoidosis.

Authors:  B A Mc Ardle; E Leung; H Ohira; M S Cocker; R A deKemp; J DaSilva; D Birnie; R S Beanlands; P B Nery
Journal:  J Nucl Cardiol       Date:  2013-01-04       Impact factor: 5.952

Review 9.  Cardiomyopathies: Evolution of pathogenesis concepts and potential for new therapies.

Authors:  Hamayak Sisakian
Journal:  World J Cardiol       Date:  2014-06-26

10.  Reduction in ¹⁸F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis.

Authors:  Michael T Osborne; Edward A Hulten; Avinainder Singh; Alfonso H Waller; Marcio S Bittencourt; Garrick C Stewart; Jon Hainer; Venkatesh L Murthy; Hicham Skali; Sharmila Dorbala; Marcelo F Di Carli; Ron Blankstein
Journal:  J Nucl Cardiol       Date:  2013-12-03       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.